Jiangsu Lianhuan Pharmaceutical Co., Ltd. (600513.SS)
- Previous Close
8.54 - Open
8.50 - Bid 8.45 x --
- Ask 8.46 x --
- Day's Range
8.38 - 8.57 - 52 Week Range
6.71 - 14.40 - Volume
4,886,901 - Avg. Volume
8,051,094 - Market Cap (intraday)
2.412B - Beta (5Y Monthly) 0.41
- PE Ratio (TTM)
17.98 - EPS (TTM)
0.47 - Earnings Date --
- Forward Dividend & Yield 0.15 (1.76%)
- Ex-Dividend Date May 26, 2023
- 1y Target Est
--
Jiangsu Lianhuan Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals, preparations, and API products in China. The company offers clopidogrel bisulfate tablets used to prevent atherothrombotic events; azithromycin tablets for the treatment of mild to moderate infections caused by susceptible strains of designated microorganisms; milrinone injection for short-term intravenous therapy in patients with acute compensated heart failure; and dapoxetine hydrochloride tablets for the treatment of premature ejaculation in men, as well as epulet, ebastine, felodipine, and terfenadine tablets, drotaverine hydrochloride injection, and danazol suppository. It also offers preparation products, which covers urinary system, antihistamines, cardiovascular drugs, steroid hormones, and antibiotics. In addition, the company engages in the wholesale of chemical raw materials and pharmaceuticals, as well as provides technological transfers and technical consultation services. It exports its products to Southeast Asia, North America, South America, Europe, New Zealand, Australia, and other countries. The company was founded in 1999 and is headquartered in Yangzhou, China.
www.lhpharma.com1,296
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: 600513.SS
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 600513.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 600513.SS
Valuation Measures
Market Cap
2.44B
Enterprise Value
2.86B
Trailing P/E
18.17
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.13
Price/Book (mrq)
1.80
Enterprise Value/Revenue
1.32
Enterprise Value/EBITDA
11.09
Financial Highlights
Profitability and Income Statement
Profit Margin
6.21%
Return on Assets (ttm)
4.04%
Return on Equity (ttm)
10.33%
Revenue (ttm)
2.17B
Net Income Avi to Common (ttm)
135.01M
Diluted EPS (ttm)
0.47
Balance Sheet and Cash Flow
Total Cash (mrq)
281.38M
Total Debt/Equity (mrq)
46.51%
Levered Free Cash Flow (ttm)
-65.42M